SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000020
Filing Date
2021-02-23
Accepted
2021-02-23 16:05:10
Documents
15
Period of Report
2021-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210223.htm   iXBRL 8-K 36285
2 EX-99.1 adms2020q4991.htm EX-99.1 76478
  Complete submission text file 0001328143-21-000020.txt   270672

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210223.xsd EX-101.SCH 2423
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20210223_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20210223_def.xml EX-101.DEF 1643
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210223_lab.xml EX-101.LAB 26042
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210223_pre.xml EX-101.PRE 14071
8 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210223_htm.xml XML 10978
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 21665364
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences